OFFICE HOURS
Chapter Two: Office Hours
She would remember, afterward, the particular quality of his silence when he was deciding whether to say something he had not planned to say, and she would remember that the first time she heard it was in that fourth floor office, the September light slanting gold across the desk between them, long before she understood what the silence meant.
That came at the end. First, Thursday.
Thursday arrived with the specific weight of a day that had been anticipated for three full days, which Zoe would not have admitted to anyone, least of all herself, except that denying it required more energy than simply acknowledging it and moving on.
She had prepared the way she prepared for any argument she intended to make, not by scripting what she would say, because good arguments were never scripts, but by understanding the material well enough that she could answer anything thrown at her. The case for the next session was a private equity restructuring with three possible outcomes, two of them obvious and being presented to the class as the only real choices, and one that Ashford had, she suspected, seeded into the case precisely because it was the right answer no one would reach without being pushed hard enough to find it.
She had reached it Tuesday evening. She had spent Wednesday testing it from every angle she could think of, and a few she had to invent.
His office hours were held on the fourth floor of the Whitmore faculty wing, a space entirely different from the classrooms in the way a person's private rooms differ from their public face, not less professional but more revealing. The bookshelves were dense and organised according to a logic that was not alphabetical and not arranged by any obvious taxonomy, and she found herself wanting, with an intensity that startled her, to understand the system well enough that it would make sense.
He was at his desk when she came in at two exactly. He looked up, and something in his face arranged itself, briefly, into an expression she could not name and would spend the next hour trying not to think about.
"Ms. Hart," he said.
"Professor Ashford," she said.
He indicated the chair across the desk. She sat. A copy of the case file lay between them, and she was aware, in a way she resented, of the precise distance between his hand resting near the folder and her own on the arm of the chair.
"What did you find," he said.
"The third option," she said.
He studied her for a beat that lasted slightly longer than the question warranted. "There are two obvious options," she went on. "Accept the buyout at current valuation, or counter propose at a higher multiple. The class will argue about which of those two is correct."
"And," he countered.
"Neither is," she said. "The third option is a partial recapitalisation with retained operational control. The private equity firm gets the liquidity event it needs through a preferred equity structure. The family keeps the voting majority."
"Walk me through the numbers," he said, and settled back in his chair with the particular stillness of a man who intended to listen all the way through before he moved to break anything.
She did. He let her run for four full minutes without interruption, which she had already learned, from one previous session, meant he was listening to the architecture of the argument rather than its content, hunting for the place it would give way.
"The preferred equity structure," he said finally. "You're assuming a convertible preferred with a participating clause. Why."
"Because a straight preferred creates an alignment problem at exit," she said. "The private equity firm wants capital appreciation. Cap them at the preferred return and they have no incentive to grow the business. A participating clause aligns the incentives."
"And if the family's growth projections are wrong," he said.
"Then the participating clause hurts them at exit," she said. "If the business underperforms, they've surrendered more economics than a straight buyout would have cost."
"So the risk is asymmetric," he pressed.
"All the risk in this structure is asymmetric," she said. "The question is which direction you prefer it to run."
He leaned forward slightly, and the September light caught the grey at his temple, and she lost, for perhaps half a second, the thread of her own sentence before she caught it again. Finish the point, she told herself. He is testing an argument, not you. Except that some part of her no longer believed the two could be fully separated.
"Preferred direction of risk," he said. "Define it."
"Downside belongs to the family," she said. "Upside is shared. Which is actually the appropriate structure if you believe in the business. You aren't selling the upside, you're selling the floor."
"What if the family doesn't believe in the business," he said.
"Then they should take the straight buyout," she said. "The recapitalisation only works if the family's growth thesis is stronger than the market's. If they agree with the market's valuation, they should accept market terms."
"And if they have information the market doesn't," he said.
"Then the recapitalisation is mispriced in their favour," she said. "Which is the whole thesis."
He was quiet a moment. Outside the fourth floor window, Cambridge in September wore the specific golden quality of early autumn, the trees not yet turning, the light still warm enough to feel like permission for something.
"The flaw," he allowed.
"Information asymmetry cuts both ways," she said. "If the family has private information that supports the growth thesis, the private equity firm knows there's private information. They'll price the preferred structure to account for it."
"How," he returned.
"A ratchet mechanism," she said. "If the business hits certain milestones, the family retains more equity. If it misses them, the firm gets additional shares. The family is essentially betting their ownership stake against the market's scepticism."
"Is that a flaw or a feature," he said.
She held his gaze longer than the question strictly required. "Both," she said. "It's a flaw because the ratchet has to be negotiated, which means revealing enough of the private thesis to agree on milestones. That reduces the asymmetry. It's a feature because it puts everyone's money where their conviction is."
"Good," he said, and it was not effusive, it was precise, the specific satisfaction of a man who had heard exactly what he was listening for and felt it land somewhere he did not entirely control.
"The class won't get there," he put in.
"No," she agreed.
"Why not," he said, unhurried.
"Because the buyout frame is given," she said. "The case presents it as a binary, accept or counter. Reaching the recapitalisation requires rejecting the frame the case hands you."
"And you rejected it," he said, after a moment.
"Yes."
"Why," he said, and this time his voice had dropped, the register she had already begun, privately, to think of as his real one.
"Because the case is about a family that spent forty years building something," she said, "and the private equity offer is structured to make the decision feel like it's about price. It isn't. It's about whether they're willing to exit. The recapitalisation only becomes visible once you've already decided they aren't."
"What made you decide that," he said.
"There's a line in the case note," she said. "About the founder's grandfather. The business is named after him. You don't keep a company named after your grandfather because you're ready to sell it."
He looked at her for a long moment, long enough that the office seemed to contract slightly around the two of them, the bookshelves and the September window receding to the edges of her attention. "That's an inference from a biographical detail," he said.
"Yes."
"Finance doesn't run on biographical inferences," he said.
"Finance runs on models," she said. "Models run on assumptions. The assumption about whether the family is willing to exit is the most important input in the model, and it's the one nobody ever asks about explicitly."
He was quiet again, longer this time, and she found she did not mind the silence nearly as much as she probably should have.
"Most of my students," he said eventually, "spend the first month of this course learning to read a balance sheet."
"I can read a balance sheet," she countered.
"I know," he said. "That isn't what I mean."
"What do you mean," she shot back.
He looked down at the case file, and when he spoke again something in his voice had shifted, become more careful, as though he were choosing each word the way she chose numbers. "You're arguing that the most important financial input is a non-financial one."
"I'm arguing that the best financial models identify where the financial inputs depend on non-financial truths," she said. "The discount rate depends on the family's actual risk tolerance. The growth projections depend on whether the founder still believes in the business. The exit timing depends on what they want their lives to look like in five years."
"Behavioural questions," he said.
"Yes."
"Which makes finance a behavioural science," he said.
"At the margin," she said. "Where all the important decisions actually happen."
He looked at her, and for a moment the careful quality that governed his face slipped, very slightly, into something warmer and considerably more dangerous. "Do you have another class after this," he said.
"No," she allowed.
"I'm going to give you the next three cases," he said, opening a drawer. "Not the ones on the syllabus. Supplemental material. I want to see how your argument holds when the non-financial inputs are harder to read."
"Harder how," she returned.
"One of them is a company where the chief executive is lying," he said. "Not obviously. The financial model is internally consistent. The lie is in the strategic narrative, and the only way to see it is to understand what the model assumes about management quality."
"Management quality as a non-financial input," she said.
"That one," he said, "has no clean answer. It has been in my teaching file for six years, and no one has proposed a satisfactory resolution."
"What's the closest anyone's gotten," she pointed out.
"You're not supposed to ask that," he said. "It contaminates the analysis."
"It tells me the shape of the space where solutions exist," she said.
He repeated it slowly, as though testing the phrase's weight. "The shape of the space where solutions exist."
"If the closest anyone's gotten is a partial solution of a specific kind," she said, "I know which directions have been exhausted. I can look somewhere else."
"That's a reasonable argument for asking," he countered.
"Thank you."
"The answer," he said, "is that the closest anyone has come involves treating the management lie as a separate asset class. Pricing the deception as a put option."
She turned that over. "A put option on integrity," she said.
"A put option on the premium the market is paying for management quality that may not exist," he said. "If the deception is discovered, the market re-rates the stock. The put captures the downside."
"That assumes you know the deception exists," she said. "If you know it exists, you can short the stock directly. The put is only useful if you're uncertain."
"Everyone is uncertain," he pressed.
"Then the put option is just a hedge against your own uncertainty about whether your analysis is correct," she said. "Not a solution to the problem."
He studied her, something sharpening in his expression, pleasure disguised, not very successfully, as professional interest. "You've just invalidated six years of student solutions," he said.
"I've invalidated the most popular direction," she said. "That doesn't mean there isn't a better one."
"There isn't," he said. "That's what makes it a teaching case."
"Then the lesson is that some problems don't have solutions," she said.
"Some problems," he said, "have solutions that are outside the frame the problem presents. Like your recapitalisation."
She looked at him properly then, and the office felt suddenly very small, the distance across the desk a thing she was abruptly, inconveniently aware of in her whole body. "The chief executive case," she said, steadying her voice. "Is the lie about the financials, or the strategy."
"Strategy," he allowed.
"Then the solution space is the question of what the correct strategy actually is," she said. "Not what the current management claims to be doing. The company's value isn't determined by what the chief executive says, it's determined by what the underlying business can actually do. The deception is noise. Find the signal."
"The signal," he said, very quietly.
"The assets, the market position, the competitive advantage that exists independent of management's narrative," she said. "Price those. Let the deception eventually correct itself. When it does, you've bought the real business at a discount."
"You're describing a value investing thesis," he said.
"Yes."
"Which requires holding through the deception's unwind," he said. "Which can take years."
"Value investing always requires holding through pain," she said. "That's the premium you collect for doing the analysis correctly."
He was quiet for a long moment, the September office around them, and when he finally opened the folder and slid it across the desk, his fingers lingered on the edge of it a half second longer than the gesture required, close enough to hers that she felt the warmth of his hand before either of them had touched anything.
"The three cases," he said. "The chief executive one is the middle case. I want it last."
"Why," she said, holding his gaze.
"Because the way you approach the first two will tell me how to read your approach to the third," he said.
She took the folder, aware of her own pulse in a way she had not been aware of it in years, not since adolescence, not since whatever version of herself had still believed attraction was something that happened to other people, in other rooms, under less supervised circumstances. "Professor Ashford," she said.
"Yes."
"Is this how you teach everyone," she said, after a beat.
He looked at her for a long, measuring moment. "No," he said. "Most students receive the standard syllabus."
"Then why," she started.
"Because the standard syllabus is designed to teach people how to read financial models," he said. "You already know how to read financial models. What you are developing is a theory."
"A theory," she said.
"About what finance actually is," he said. "The behavioural margin you mentioned. The non-financial inputs that determine the financial outputs. You are working toward a thesis, and I don't think you know it yet."
"And you think the three supplemental cases will," she started again.
"Test it," he said. "If the thesis holds against all three, you have something. If it doesn't, you'll know where the boundaries are."
She looked down at the folder in her hands. A theory, she thought. He thinks I'm developing a theory, and he's given me three cases to test it against, and I would very much like to know what else he thinks about me that he hasn't said yet.
"Thursday," he said. "Same time. Bring me the first case."
"One week," she said.
"Is that not enough," he returned.
"It's enough," she countered.
"Good," he noted.
She stood, put the folder in her bag, and said, "Thank you," and he said, "Ms. Hart," in a tone that stopped her halfway to the door.
"Yes," she said, steady.
"The recapitalisation argument," he said. "On Tuesday, bring it as your main contribution. Not as a suggestion, as the argument. Make the class defend the buyout frame they've accepted. Don't give them the alternative. Make them find it."
"You want me to Socratic them," she allowed.
"I want to find out," he said, "if the argument is strong enough to hold under examination. The best test of an argument is whether it can generate the right questions."
"And if they don't find the recapitalisation option," she said.
"Then we'll know the argument needs to be made more explicitly," he said. "And you'll learn something about making arguments for people who haven't already rejected the frame."
He's teaching me to argue, she thought, walking out into the September corridor, the weight of the folder in her bag entirely out of proportion to its actual contents. Not just to analyse. To argue. The difference is the audience.
The first case took her two days. It was a pharmaceutical licensing deal, a small biotech company with a compound in Phase Two trials, a major pharmaceutical firm circling to acquire the intellectual property at a stage gate price. The non-financial input was clinical trial uncertainty, the probability the compound would hit its Phase Three endpoints, which the biotech's own management had modelled at seventy two percent.
The market was pricing the deal as though the probability were forty five percent.
The gap, twenty seven percentage points, was the entire argument.
She spent the first day with the clinical data, which she was honest enough to admit she was not scientifically qualified to evaluate. What she could evaluate was whether the biotech's methodology was internally consistent with the published literature on compounds of that class. It was. Their endpoint assumptions were, if anything, conservative relative to the published comparables.
So the market was either wrong about the compound, or right about something the clinical data wasn't showing.
The second day she found it, buried in the management team's publication history. Three of the four co-founders had previous Phase Two to Phase Three attrition rates significantly worse than the published literature for similar compounds, not because their science was bad, their papers were well cited and their methodology sound, but because they were aggressive optimists in trial design. They reached Phase Two with ambitious endpoints and failed Phase Three because the ambitious endpoints were harder to hit than the conservative alternatives would have been.
The market wasn't pricing the compound at forty five percent. It was pricing the founders.
She brought it to Thursday office hours, and he read the analysis in silence for three full minutes, and she was beginning to understand that three minutes of silence from Daniel Ashford meant the argument was passing first order inspection, and that the understanding itself had become, somewhere in the last week, a small private pleasure she did not examine too closely.
"The management track record," he said. "How did you find it."
"Publication history," she said. "Their previous clinical work."
"Most students don't look at publication history," he said.
"Most financial models don't include it," she returned.
"Why did you," he put in.
"Because you told me the non-financial inputs are where the important decisions live," she said. "Management quality is a non-financial input. The way to evaluate it in biotech isn't the balance sheet, it's the science."
"You're not a scientist," he said, unhurried.
"No," she said. "But I can evaluate whether their methodology is consistent with the field, and I can track their historical endpoint selection against their historical outcomes."
"Which is what the market has done," he said, after a moment.
"Yes. The market is right. It just doesn't know it's right for the right reasons."
He looked at her, and something in his posture, the way he leaned forward slightly over the desk, made her acutely conscious of the small distance still separating them. "Explain," he said.
"The market has priced the management discount based on the previous failures," she said, "but it hasn't specified the mechanism. It doesn't know whether the failures came from bad science, bad trial design, or ambitious endpoint selection. The mechanism matters, because it determines whether the discount should apply to this compound."
"Why," he said.
"If it's bad science, the discount applies," she said. "The compound probably fails regardless of endpoints. If it's ambitious endpoint selection, overconfidence in what the compound can do, then the discount only applies here if they've set ambitious endpoints again."
"Have they," he said.
"Yes," she said. "But conservatively ambitious. Aggressive relative to the published comparables, not aggressive relative to what the Phase Two results actually suggest the compound can do."
"So they've learned something," he countered.
"Or they've simply had one genuinely stronger compound," she said. "I can't distinguish between those with the data I have."
"Which is the honest statement of your analytical position," he said.
"Yes."
"What does that tell you about the deal," he pressed.
"That the gap between the market price and the biotech's own valuation is the price of that uncertainty," she said. "If you believe they've learned, you're buying a discount that shouldn't be there. If you believe they haven't, the market is right."
"What do you believe," he said, and his voice had gone low again, the register that made her abruptly aware of the office's quiet, the closed door, the two of them and the folder and the long afternoon light.
"I believe the compound's data is strong and the endpoints are calibrated more carefully than their previous work," she said. "I believe the discount is too large relative to the specific compound quality. But I acknowledge the management team's track record is real evidence, and I can't fully price the learning question."
"So your recommendation is," he allowed.
"Structure the deal to separate the management question from the compound question," she said. "Stage gate it with milestone payments. Pay the biotech on Phase Three initiation at the forty five percent price. Pay the full premium only if they hit the Phase Three endpoints."
"You're making the management team bear the risk of their own track record," he said.
"Yes. If they've learned, they'll accept the structure. If they haven't, the milestone payments protect the acquirer from the discount they'd otherwise pay upfront."
He set the analysis down. "That," he said, "is a clean solution."
"Thank you."
"It's also the solution a deal lawyer would tell you is extremely difficult to negotiate," he said.
"Because the milestone definitions are contested," she said.
"Because every milestone in a stage gate is a negotiation over what counts as success," he said, "and the biotech's founders will have a different definition than the acquirer's clinical team."
"That's a deal structure problem," she said. "Not an analytical one."
"Yes," he said. "The analysis is sound. The implementation is complicated. That distinction matters."
"In what sense," she pointed out.
"In the sense," he said, "that most finance careers are spent navigating the gap between the analytically correct answer and the implementable one. Knowing the gap exists, knowing where the clean solution ends and the negotiation begins, is a skill."
He's teaching me to know where my own argument ends, she thought.
"I'm teaching you," he said, as though he had heard it, "to know what your argument is for."
"What do you mean," she said, holding his gaze.
"Is the argument for yourself," he said, "to prove you've found the right answer. Or is it for the deal, to reach an outcome actually better than what would happen without it."
She was quiet.
"If it's for yourself," he said, "the stage gate is a demonstration of analytical clarity. If it's for the deal, it has to be negotiable. Those require different arguments."
"The deal," she said. "Always the deal."
"Good," he said, and something in the single syllable reached further than the word should have, landing low in her chest and staying there.
She stood, folder in hand, and at the door she turned back once. "Professor Ashford," she said.
"Yes."
"The chief executive case," she said. "The one with no clean solution."
"Next week," he returned.
"I'm ready now," she said, after a beat.
He studied her for a long moment, something considering and faintly amused moving behind his eyes. "The value investing argument you made last week," he said. "I want to see if it holds after the first two cases."
"You think the pharmaceutical case will change how I approach it," she said.
"I think it's taught you something about the difference between the analytically correct answer and the implementable one," he said. "I want to see if you apply it to a harder problem."
"You said there's no clean answer," she said.
"No one has found one," he said. "That doesn't mean there isn't one."
Outside, the September afternoon had turned toward evening, the fourth floor window holding the last of the gold light, Cambridge slipping slowly toward the colour it would wear for the rest of the autumn. A theory, she thought, descending the stairs. And now it has a shape. The analytically correct answer and the implementable one. The gap between them is where the argument has to live.
Yes, she thought.
I'm beginning to see it.